-
‘Naively Ambitious’: How COVAX Failed on its Promise to Vaccinate the World Opens in a new window)
Conceived at the start of the pandemic, COVAX had lofty goals, promising fair and equitable access to Covid-19 vaccines for every country worldwide, and giving them for free to the poorest. -
Buyers Clamor for Merck's COVID-19 Antiviral Molnupiravir, but Pricing is Already Controversial Opens in a new window)
Less than a week after Merck and Ridgeback released extraordinary data on the effectiveness of experimental COVID-19 drug molnupiravir, the rush is on to lock up supplies.Comments
-
WHO Prioritizes Access to Diabetes and Cancer Treatments in New Essential Medicines Lists Opens in a new window)
High prices and low availability still a major barrier for patients’ access to new and old medicines.Comments
-
For the First Time, WHO Committee Recommends Action on High-Priced Essential Medicines Opens in a new window)
The suggestion was made in the latest report about treatments to be added to the WHO list of essential medicines.Comments
-
The U.S. Can Lower Drug Prices Without Sacrificing Innovation Opens in a new window)
Large pharmaceutical companies are nowhere near as important to real drug innovation as they purport to be.Comments
-
Merck’s New Covid-19 Drug Could be One of the Most Lucrative Drugs Ever Opens in a new window)
The drug, named molnupiravir, reduces the risk of hospitalization or death by 50% in Covid-19 patients with mild and moderate symptoms compared with placebo, Merck said.Comments
-
Virtual Event
The evolving landscape for biosimilars.Comments
-
Drug Companies Are Still Under Scrutiny For Drug Price Gouging Opens in a new window)
The pharma industry has struggled for years with a poor reputation due to high drug prices and unethical business practices.Comments
-
What's Fueling the World's Covid-19 Vaccination Disparity?
Amnesty international has warned covid-19 developers not to put profits before lives.Comments
-
COVID-19 Pandemic Cut Life Expectancy by Most Since World War Two Opens in a new window)
Overall, men had more than a year shaved off in 15 countries, compared to women in 11 countries.Comments
-
WHO Adds Regeneron Drug to Recommended Covid-19 Treatments, but Criticizes its Pricing Opens in a new window)
As part of their message, the agencies also urged Regeneron to transfer technology used to make its monoclonal antibody to other manufacturers so that lower-cost biosimilar versions could be made more quickly for low and middle-income nations.Comments
-
A W.H.O. Panel Recommends Treating High-Risk Covid Patients with Monoclonal Antibodies. Opens in a new window)
In the United States, some health experts have worried that promoting the therapy, which the government covers at a cost of $2,100 per dose, was taking away time and money from the effort to get more Americans vaccinated against Covid.Comments
-
WHO Backs Regeneron Drug for COVID-19, Urges Action on Price Opens in a new window)
The health agency urged Regeneron, which holds the patent, to lower the drug’s price and work on equitable distribution worldwide.Comments
-
A Double Dose of Inequality: Pharma Companies and the Covid-19 Vaccines Crisis
New report shows leading Covid-19 vaccine pharma companies fuelling unprecedented human rights crisis.Comments
-
WHO Backs Regeneron COVID-19 Drug Cocktail as UN Body Calls for Equal Access Opens in a new window)
The treatment has been granted U.S. emergency use authorisation, having gained attention when used to treat former President Donald Trump's COVID-19 illness last year.Comments
Comments